Litcius/Paper detail

Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours

Panagiotis A. Konstantinopoulos, Su–Chun Cheng, Jeffrey G. Supko, Madeline Polak, Andrea E. Wahner-Hendrickson, S. Percy Ivy, Brittany Bowes, Hannah Sawyer, Patrice Basada, Martin Hayes, Jennifer Curtis, Neil S. Horowitz, Alexi A. Wright, Susana M. Campos, Elena V. Ivanova, Cloud P. Paweletz, Sangeetha Palakurthi, Joyce F. Liu, Alan D. D’Andrea, Prafulla C. Gokhale, Dipanjan Chowdhury, Ursula A. Matulonis, Geoffrey I. Shapiro

2021British Journal of Cancer35 citationsDOIOpen Access PDF

Topics & Concepts

OlaparibTolerabilityPARP inhibitorMedicinePharmacokineticsSynthetic lethalityOvarian cancerPharmacologyOncologyCancer researchInternal medicineAdverse effectCancerBiologyPoly ADP ribose polymeraseDNA repairBiochemistryGenePolymerasePARP inhibition in cancer therapyHeat shock proteins researchDNA Repair Mechanisms